Single comment threadYou are looking at one branch of MASH vs biopsy — genuinely asking which matters more — 8 comments in the full submission. View in context.
0
MASH vs biopsy — genuinely asking which matters more
dual agonist. That is the whole post, but I will justify it. Everything else people worry about in c/compounding is downstream of it. Titration speed, muscle cramps, the endless dose arguments — most of it resolves if you sort dual agonist out first, and almost nobody does. I say this having got it wrong for 15…
Yeah, glucagon co-agonism is genuinely different.
Which trial arm?
Disagree but this is the good kind of wrong — it is specific enough to be checked.
Which trial arm?
glucagon co-agonism has a different safety story
glucagon injection is a different vector than GLP-1
glucagon injection is a different vector than GLP-1
Yes, exactly this, and it is the bit that took me 69 weeks to accept.
MASH claims need the trial and the biopsy endpoint